NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc. Stock News
$0.435
+0.0570 (+15.10%)
At Close: May 01, 2024
Children’s Healing Art Project (CHAP) Launches #CHAPPYFEET Challenge
12:00am, Wednesday, 20'th May 2020
Make Art With Your Feet. The CHAPpy Feet Challenge FUNdraiser Brings Art To Kids and Families In Medical Crisis. Help The Non-Profit Bring Art to Kids
Does The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Share Price Tend To Follow The Market?
10:06am, Monday, 18'th May 2020
If you own shares in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) then it's worth thinking about how it contributes...
QurAlis raises $42M in Series A round to develop therapies for ALS
03:00pm, Sunday, 17'th May 2020
Startup companies that have raised closed funding rounds in the past week also include C2N Diagnostics, Carbon Health, Stellar Health and Modulus Discovery.
How to buy ALS shares | 18 May price A$6.28 | Finder
11:27pm, Wednesday, 13'th May 2020
Ever wondered how to buy shares in ALS? We explain how and compare the best share trading platforms. Latest ALS share price is A$6.28.
Non-Small Cell Lung Cancer (NSCLC) Market Insights and Epidemiology 2017-2030 - ResearchAndMarkets.com
12:00am, Monday, 11'th May 2020
The
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript
07:46pm, Sunday, 10'th May 2020
BrainStorm Cell Therapeutics Inc. BCLI) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits -
BCLI: The Countdown to Phase 3 ALS Data Begins…
09:35am, Friday, 08'th May 2020
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Topline Data in 4Q20 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 c
Brainstorm Cell Q1 EPS $(0.320) Misses $(0.220) Estimate
10:42am, Thursday, 07'th May 2020BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
10:30am, Thursday, 07'th May 2020
Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 -- BrainStorm.
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
09:33am, Thursday, 07'th May 2020BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
05:00am, Thursday, 07'th May 2020
NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
07:30am, Monday, 04'th May 2020
NEW YORK, May 04, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced.
